This guideline covers good practice for developing, authorising, using and updating patient group directions. It also offers advice on deciding whether a patient group direction is needed.
This guideline covers good practice for developing and updating local formularies in line with statutory requirements. It supports developing formularies that reflect local needs, reduce variation in prescribing, and allow rapid adoption of new medicines and treatments.
This guideline covers the effective use of antimicrobials (including antibiotics) in children, young people and adults. It aims to change prescribing practice to help slow the emergence of antimicrobial resistance and ensure that antimicrobials remain an effective treatment for infection.
This guideline covers systems and processes for using and managing controlled drugs safely in all NHS settings except care homes. It aims to improve working practices to comply with legislation and have robust governance arrangements. It also aims to reduce the safety risks associated with controlled drugs.
This guideline covers medicines support for adults (aged 18 and over) who are receiving social care in the community. It aims to ensure that people who receive social care are supported to take and look after their medicines effectively and safely at home. It gives advice on assessing if people need help with managing their medicines, who should provide medicines support and how health and social care staff should work together.
Evidence-based recommendations on lead-I ECG devices for detecting symptomatic atrial fibrillation using single time point testing in primary care
Evidence-based recommendations on tumour profiling tests to guide adjuvant chemotherapy decisions in early breast cancer
Evidence-based recommendations on biomarker tests (Actim Partus, PartoSure, Rapid fFN 10Q Cassette) to diagnose preterm labour in women with intact membranes
Evidence-based recommendations on DYSIS colposcope with DYSISmap and ZedScan I for assessing suspected cervical abnormalities in people having colposcopy
Evidence-based recommendations on tests (IOTA ADNEX, Overa, RMI I, ROMA, IOTA Simple Rules) in secondary care to identify people at high risk of ovarian cancer
Evidence-based recommendations on quantitative faecal immunochemical tests (OC Sensor, HM-JACKarc and FOB Gold) to guide GP referral for colorectal cancer
Evidence-based recommendations on new generation computed tomography (CT) scanners for cardiac imaging for suspected or known coronary artery disease
Evidence-based recommendations on multi frequency bioimpedance devices to guide fluid management for people with chronic kidney disease having dialysis
Evidence-based recommendations on virtual chromoendoscopy (VCE) using NBI, FICE or i-scan to assess colorectal polyps of 5 mm or less during colonoscopy
Evidence-based recommendations on immunohistochemistry/microsatellite instability testing to guide tests for Lynch syndrome in people with colon cancer
Evidence-based recommendations on integrated multiplex polymerase chain tests for identifying gastrointestinal pathogens in suspected gastroenteritis
Evidence-based recommendations on high-throughput non-invasive prenatal testing (NIPT) for fetal RHD genotype
Evidence-based recommendations on ImmunoCAP ISAC 112 and Microtest for multiplex allergen testing to diagnose allergy and predict the risk of allergic reaction
Evidence-based recommendations on PlGF-based testing to help diagnose suspected pre-eclampsia
Evidence-based recommendations on therapeutic monitoring of TNF-alpha inhibitors in Crohn’s disease
Evidence-based recommendations on the MiniMed Paradigm Veo and Vibe and G4 PLATINUM CGM sensor-augmented pump therapy systems for type 1 diabetes
Evidence-based recommendations on the LightCycler SeptiFast Test MGRADE, SepsiTest and IRIDICA BAC BSI assay for identifying bloodstream bacteria and fungi
Evidence-based recommendations on VivaScope 1500 and 3000 imaging systems for detecting skin cancer lesions
Evidence-based recommendations on procalcitonin testing for diagnosing and monitoring sepsis (AVIDA Centaur BRAHMS PCT assay, BRAHMS PCT Sensitive..
Evidence-based recommendations on high-sensitivity troponin tests for the early rule-out of acute myocardial infarction (AMI)
Evidence-based recommendations on point-of-care coagulometers (the CoaguChek XS system) to self-monitor blood clotting
Evidence-based recommendations on the NIOX MINO, NIOX VERO and Nobreath devices to measure fractional exhaled nitric oxide concentration in asthma
Evidence-based recommendations on faecal calprotectin diagnostic tests for inflammatory diseases of the bowel
Evidence-based recommendations on the EOS 2D/3D imaging system for radiological examinations
Evidence-based recommendations on SeHCAT (tauroselcholic [75 selenium] acid) for investigating diarrhoea due to bile acid malabsorption (BAM)
Evidence-based recommendations on the Bispectral Index (BIS), E-Entropy and Narcotrend-Compact M depth of anaesthesia monitors
Evidence-based recommendations on theSonoVue (sulphur hexafluoride microbubbles) contrast agent for contrast-enhanced ultrasound imaging of the liver
Evidence-based recommendations on enzyme-linked immunosorbent assay (ELISA) tests for therapeutic monitoring of TNF-alpha inhibitors in rheumatoid arthritis
Evidence-based recommendations on rapid tests for group A streptococcal (strep A) infections in people aged 5 and over with a sore throat
Evidence-based recommendations on point-of-care creatinine devices to assess kidney function before CT imaging with intravenous contrast
Evidence-based recommendations on the RD-100i OSNA system and Metasin test for detecting sentinel lymph node metastases in breast cancer
Evidence-based recommendations on EGFR-TK mutation testing in adults with locally advanced or metastatic non-small-cell lung cancer (NSCLC)
Evidence-based recommendations on viscoelastometric point-of-care testing (ROTEM, TEG and Sonoclot systems) to detect, manage and monitor haemostasis
Evidence-based recommendations on the My5-FU assay for guiding dose adjustment for fluorouracil chemotherapy
In development [GID-DG10033] Expected publication date: 29 July 2020
In development [GID-DG10034] Expected publication date: 30 September 2020
In development [GID-DG10035] Expected publication date: 26 August 2020
In development [GID-DG10023] Expected publication date: 27 May 2020
We are listening to your views on this diagnostics guidance. Comments close 04 February 2020.
In development [GID-DG10029] Expected publication date: 26 August 2020
In development [GID-DG10028] Expected publication date: 22 April 2020
In development [GID-DT9] Expected publication date: TBC
In development [GID-DT14] Expected publication date: TBC
In development [GID-DT28] Expected publication date: TBC
Both index tests included in this guidance are no longer commercially available. Therefore the guidance has been withdrawn.